Method for preventing and / or treating virus infections

By administering LRPAP1 inhibitors, particularly α2-macroglobulin, the binding of LRPAP1 to IFNAR1 is blocked, and the interferon signaling pathway is enhanced, thus solving the problem of viral evasion of host defense and improving the ability to defend against viral infection, especially in the central nervous system.

CN120936381APending Publication Date: 2025-11-11CITY UNIVERSITY OF HONG KONG
0 Cites 0 Cited by

Patent Information

Application Number
CN202480019515.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-05
Filing Date
2024-05-03
Publication Date
2025-11-11

AI Technical Summary

Technical Problem

Viruses target intracellular interferon signaling pathways through multiple mechanisms, weakening the host cell's innate immune response. In particular, in the central nervous system, current technologies struggle to effectively block viruses from circumventing the host's defense mechanisms.

Method used

Subjects were given low-density lipoprotein receptor-associated protein 1 (LRPAP1) inhibitors to target LRPAP1 and increase the expression levels of interferon and its derivatives, protect interferon α/β receptor 1 (IFNAR1), and block the binding of LRPAP1 to IFNAR1 using LRPAP1 inhibitors such as α2-macroglobulin or siRNA.

Benefits of technology

It enhances innate immunity to a variety of viral infections, reduces viral infection levels, including the damage of RNA and DNA viruses to nerve cells, and reduces the risk of acute and chronic neurological diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses a virus protease, EV71 2Apro and SARS-CoV-23CLpro, which can promote the extracellular level of LRPAP1 to be increased, and the LRPAP1 can degrade IFNAR1 (interferon-related protein 1) and inhibit subsequent interferon signal transduction. In addition, the inhibition of LRPAP1 by a composition containing alpha2M, siRNA, or other LRPAP1 inhibitors can improve RNA virus and DNA virus infections. The invention not only expands the relevance between lipoprotein metabolism and host innate immune response, but also lays a foundation for the development of broad-spectrum antiviral drugs.
Need to check novelty before this filing date? Find Prior Art